Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $12.49, but opened at $12.97. Replimune Group shares last traded at $12.44, with a volume of 74,714 shares changing hands.

Analysts Set New Price Targets

A number of research analysts have recently commented on REPL shares. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a report on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, December 4th. Finally, Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $17.29.

Replimune Group Price Performance

The stock has a market cap of $844.27 million, a price-to-earnings ratio of -4.05 and a beta of 1.26. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The company's 50-day moving average is $12.28 and its 200-day moving average is $10.80.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities research analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quest Partners LLC lifted its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Algert Global LLC lifted its holdings in Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company's stock worth $756,000 after buying an additional 4,340 shares in the last quarter. Creative Planning boosted its position in Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company's stock valued at $231,000 after buying an additional 4,699 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock valued at $45,000 after buying an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC raised its position in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company's stock worth $646,000 after acquiring an additional 5,410 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.